C 026: PHARMACOGENETICS: CLINICAL IMPLICATIONS FOR EATING DISORDERS AND SUICIDE

J Pharm Pharmacogn Res 2(Suppl. 1): S70, 2014

Special supplement with the abstract book of LATINFARMA 2013

Conference

C 026: PHARMACOGENETICS: CLINICAL IMPLICATIONS FOR EATING DISORDERS AND SUICIDE

Llerena A, Naranjo ME; Peñas-Lledo E.

Clinical Research Centre, Extremadura University Hospital and Medical School, Badajoz, Spain. Ibero Latino American Network of Pharmacogenetics (www.ribef.com).
Abstract

Pharmacogenomics Clinical implications. A higher frequency of CYP2D6 UMs has been found among individuals who committed suicide (Zackrisson et al., 2010). One explanation for this relationship could be treatment failure with antidepressant drugs metabolized by CYP2D6 (Llerena et al., 2004) widely used to prevent suicide or to treat mood disorders. A complementary explanation could be via the implication of the polymorphic CYP2D6 in the endogenous metabolism. CYP2D6 has been associated with behavioral and clinical risk factors such as personality and vulnerability to psychopathology (Llerena et al., 1993; 2007; Gonzalez et al., 2008; Peñas-Lledó et al., 2009, 2010). Consistently, we found a relationship between UMs and severity of suicide and lifetime history of suicidal behavior among Eating Disordered patients (Peñas-LLedó et al., 2010, 2011, 2012a). Moreover it seems also been related to antidepressant discontinuation as recently shown (Peñas-LLedó et al., 2012b). Therefore Pharmacogenomics might be useful to prevent relevant side effects such is suicide.